{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:01:58Z","timestamp":1760299318365},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1097\/md.0000000000002702","type":"journal-article","created":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T00:17:35Z","timestamp":1457137055000},"page":"e2702","source":"Crossref","is-referenced-by-count":33,"title":["Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir"],"prefix":"10.1097","volume":"95","author":[{"given":"Zobair M.","family":"Younossi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Stepanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry L.Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yock Y.","family":"Dan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon S.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210309","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1478-3231.2011.02540.x","article-title":"A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt","volume":"31","author":"Sievert","year":"2011","journal-title":"Liver Int"},{"key":"R2-10-20210309","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1620\/tjem.188.311","article-title":"Molecular epidemiology of hepatitis C virus infection in an area endemic for community-acquired acute hepatitis C","volume":"188","author":"Yoshii","year":"1999","journal-title":"Tohoku J Exp Med"},{"key":"R3-10-20210309","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/cid\/cis616","article-title":"Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence","volume":"55","author":"Spradling","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R4-10-20210309","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jhep.2013.11.014","article-title":"The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010","volume":"60","author":"Ditah","year":"2014","journal-title":"J Hepatol"},{"key":"R5-10-20210309","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","article-title":"Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010","volume":"160","author":"Denniston","year":"2014","journal-title":"Ann Intern Med"},{"key":"R6-10-20210309","doi-asserted-by":"crossref","first-page":"e0126764","DOI":"10.1371\/journal.pone.0126764","article-title":"Poovorawan Y1. Genotypic distribution of hepatitis C virus in Thailand and southeast Asia","volume":"10","author":"Wasitthankasem","year":"2015","journal-title":"PLoS One"},{"key":"R7-10-20210309","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/jmv.23399","article-title":"Distribution of hepatitis C virus genotypes in a diverse US integrated health care population","volume":"84","author":"Manos","year":"2012","journal-title":"J Med Virol"},{"key":"R8-10-20210309","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/hep.27757","article-title":"Ledipasvir\/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States","volume":"61","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"R9-10-20210309","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/cid\/civ220","article-title":"The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus","volume":"61","author":"Rein","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R10-10-20210309","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/hep.27724","article-title":"Hun. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials","volume":"61","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"R11-10-20210309","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jhep.2014.04.003","article-title":"Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study","volume":"61","author":"Younossi","year":"2014","journal-title":"J Hepatol"},{"key":"R12-10-20210309","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1002\/hep.27161","article-title":"Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens","volume":"59","author":"Younossi","year":"2014","journal-title":"Hepatology"},{"key":"R13-10-20210309","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/jvh.12227","article-title":"Work productivity among treatment-na\u00efve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment","volume":"22","author":"Aggarwal","year":"2015","journal-title":"J Viral Hepat"},{"key":"R14-10-20210309","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.cgh.2013.11.032","article-title":"Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C","volume":"12","author":"Younossi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R15-10-20210309","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/apt.13090","article-title":"Systematic review: patient-reported outcomes in chronic hepatitis C\u2013the impact of liver disease and new treatment regimens","volume":"41","author":"Younossi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R16-10-20210309","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/infdis\/jiv005","article-title":"Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes","volume":"212","author":"Younossi","year":"2015","journal-title":"J Infect Dis"},{"key":"R17-10-20210309","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1016\/j.dld.2014.09.025","article-title":"The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C","volume":"46","author":"Younossi","year":"2014","journal-title":"Dig Liver Dis"},{"key":"R18-10-20210309","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"R19-10-20210309","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"R20-10-20210309","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R21-10-20210309","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R22-10-20210309","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"R23-10-20210309","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","article-title":"Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection","volume":"312","author":"Sulkowski","year":"2014","journal-title":"JAMA"},{"key":"R24-10-20210309","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/MCG.0b013e31820d35e3","article-title":"Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial","volume":"45","author":"Hu","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"R25-10-20210309","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3109\/07853890109002089","article-title":"The RAND-36 measure of health-related quality of life","volume":"33","author":"Hays","year":"2001","journal-title":"Ann Med"},{"key":"R26-10-20210309","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36","volume":"21","author":"Brazier","year":"2002","journal-title":"J Health Econ"},{"key":"R27-10-20210309","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gut.45.2.295","article-title":"Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease","volume":"45","author":"Younossi","year":"1999","journal-title":"Gut"},{"key":"R28-10-20210309","first-page":"604","article-title":"Validation of version 4 of the core questionnaire.","volume":"8","year":"1999","journal-title":"Quality of Life Research"},{"key":"R29-10-20210309","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"PharmacoEconomics"},{"key":"R30-10-20210309","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1440-1746.2009.05789.x","article-title":"Treatment of chronic hepatitis C in Asia: when East meets West","volume":"24","author":"Yu","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"R33-10-20210309","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2893.2004.00514.x","article-title":"Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients","volume":"11","author":"Cheng","year":"2004","journal-title":"J Viral Hepat"},{"key":"R34-10-20210309","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.21683","article-title":"Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C","volume":"46","author":"Chan","year":"2007","journal-title":"Hepatology"},{"key":"R35-10-20210309","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1007\/s00520-012-1464-1","article-title":"Identifying the informational and psychosocial needs of Chinese immigrant cancer patients: a focus group study","volume":"20","author":"Leng","year":"2012","journal-title":"Support Care Cancer"},{"key":"R36-10-20210309","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1177\/0898264308315855","article-title":"Evaluating the SF-36 Health Survey (Version 2) in Older Vietnamese Americans","volume":"20","author":"Ngo-Metzger","year":"2008","journal-title":"J Aging Health"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000002702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:00:19Z","timestamp":1620961219000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201603010-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000002702","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}